<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39033579</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><Volume>271</Volume><PubDate><Year>2024</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil.</ArticleTitle><Pagination><StartPage>200</StartPage><EndPage>205</EndPage><MedlinePgn>200-205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2024.07.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0920-9964(24)00343-8</ELocationID><Abstract><AbstractText>The risk that COVID-19 poses for mortality risk in individuals with schizophrenia in low- and middle-income countries has only been the subject of a few studies. In this retrospective study, we examined the standardized mortality ratio (SMR), by age group and sex, in a cohort of patients diagnosed with schizophrenia (n&#xa0;=&#xa0;20,417), with second-generation antipsychotics, in a South Brazilian State database (Paran&#xe1;-Brazil). We performed a linkage with the Brazilian Mortality Information System database between 2020 and 2021. We also assessed in a logistic regression how clozapine could affect COVID-19 mortality controlling by sex, age, and presence of obesity. A secondary analysis was to compare mortality with SMR due to COVID-19 in individuals with and without obesity. Compared to the State population (8,850,682 individuals), those with schizophrenia had more than two times greater risk of dying from COVID-19 (SMR&#xa0;=&#xa0;2.21, 95&#xa0;% CI: 1.90-2.55). Between the ages of 16 and 29, their risk is more than ten times higher than the state population (SMR&#xa0;=&#xa0;10.18, 95&#xa0;% CI: 4.73-19.33). Obesity showed an almost twofold risk of dying from COVID-19 in the patient's group (OR&#xa0;=&#xa0;1.89, 95&#xa0;% CI: 1.39-2.57). Clozapine was not found as a protector or a risk factor for COVID-19 mortality. In Brazil, a middle-income nation, people with schizophrenia are more likely to die prematurely from COVID-19. The burden of schizophrenia is higher in younger and in patients with obesity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Diogo Fernando Bornancin</ForeName><Initials>DFB</Initials><AffiliationInfo><Affiliation>Post Graduation Program of Internal Medicine and Health Sciences, Federal University of Paran&#xe1; (UFPR), Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossignoli</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharmaceutical Assistance Coordination, Health Secretary of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontarolli</LastName><ForeName>Deise Regina Sprada</ForeName><Initials>DRS</Initials><AffiliationInfo><Affiliation>Pharmaceutical Assistance Coordination, Health Secretary of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junior</LastName><ForeName>Paulo Collodel</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Epidemiological Vigilance, Health Secretary of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assolari</LastName><ForeName>Camilla Luz</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Epidemiological Vigilance, Health Secretary of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasr</LastName><ForeName>Ac&#xe1;cia Maria Louren&#xe7;o Francisco</ForeName><Initials>AMLF</Initials><AffiliationInfo><Affiliation>Epidemiological Vigilance, Health Secretary of Paran&#xe1;, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Denise Siqueira</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Post Graduation Program of Collective Health, Federal University of Paran&#xe1; (UFPR), Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadelha</LastName><ForeName>Ary</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Federal University of S&#xe3;o Paulo (UNIFESP), S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massuda</LastName><ForeName>Raffael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Post Graduation Program of Internal Medicine and Health Sciences, Federal University of Paran&#xe1; (UFPR), Curitiba, Brazil; Department of Psychiatry, Federal University of Paran&#xe1; (UFPR), Curitiba, Brazil. Electronic address: rfmassuda@ufpr.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Low- and middle-income countries</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword></KeywordList><CoiStatement>Declaration of competing interest AG has been a consultant/advisor and/or has received honoraria from Ach&#xe9;, Daiichi-Sankyo, Torrent, Cristalia, and Janssen. DFBC has been a consultant/advisor and/or has received honoraria from Torrent. All other authors declare no competing interests. RM has been a consultant/advisor and/or has received honoraria from Daiichi-Sankyo and Janssen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>21</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39033579</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2024.07.036</ArticleId><ArticleId IdType="pii">S0920-9964(24)00343-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>